PNTC Partners to Advance Neuromuscular Disease Research

November 17, 2026
Dr. James Dowling and Dr. Drew Weissman
The Penn Neurogenetics Therapy Center (PNTC) is pleased to announce that its Director, Dr. James Dowling, is partnering with Dr. Drew Weissman, recipient of the 2023 Nobel Prize in Physiology or Medicine, on an exciting new research programme supported by AFM-Téléthon.
 
The two-year collaboration will focus on developing next-generation lipid nanoparticles (LNPs) designed to deliver genetic therapies more effectively to skeletal muscle, with the ultimate goal of advancing treatments for neuromuscular diseases.
 

Getting genetic therapies to the right place

One of the biggest challenges in gene therapy is getting treatment to the cells and tissues that need it. For neuromuscular diseases, this means finding effective ways to deliver genetic material to muscles throughout the body.
 
Dr. Dowling and Dr. Weissman are working to develop specially designed lipid nanoparticles that can carry genetic material into muscle cells while limiting its accumulation in the liver. These tiny, lipid-based particles could offer a new way to deliver genetic treatments, potentially overcoming some of the limitations of existing delivery methods.
 
The potential advantages are significant. Lipid nanoparticles can carry larger amounts of genetic material than some existing viral delivery systems and may allow treatments to be administered more than once. This could create new opportunities for developing genetic medicines, including gene-editing therapies.
 

From research to future treatments

With support from AFM-Téléthon, the research team will use artificial intelligence and advanced screening techniques to design and evaluate dozens of new nanoparticle formulations. The most promising candidates will be studied in cellular and preclinical models of Duchenne muscular dystrophy and dysferlinopathy.
 
While this research is still in its early stages, the longer-term ambition extends beyond these two conditions. A successful muscle-targeted delivery platform could potentially be adapted to support the development of genetic therapies for a much wider range of neuromuscular diseases.
 
This collaboration brings together Dr. Dowling's expertise in neuromuscular disorders and Dr. Weissman's pioneering work in mRNA technology. The funding from AFM-Téléthon represents an important investment in innovative research and the search for new treatment possibilities.
 
PNTC is excited to be part of this international collaboration and looks forward to the discoveries that may emerge from this work, bringing new hope and possibilities to individuals and families affected by neuromuscular diseases.